Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SMTI 
Sanara Medtech Inc (SMTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: SMTI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $50
1 Year Target Price $50
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.79% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 304.37M USD | Price to earnings Ratio - | 1Y Target Price 50 |
Price to earnings Ratio - | 1Y Target Price 50 | ||
Volume (30-day avg) 2 | Beta 1.19 | 52 Weeks Range 23.53 - 39.08 | Updated Date 09/17/2025 |
52 Weeks Range 23.53 - 39.08 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.22% | Operating Margin (TTM) -0.12% |
Management Effectiveness
Return on Assets (TTM) -2.5% | Return on Equity (TTM) -26.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 340786616 | Price to Sales(TTM) 3.13 |
Enterprise Value 340786616 | Price to Sales(TTM) 3.13 | ||
Enterprise Value to Revenue 3.5 | Enterprise Value to EBITDA 2320.22 | Shares Outstanding 8902351 | Shares Floating 3607589 |
Shares Outstanding 8902351 | Shares Floating 3607589 | ||
Percent Insiders 65.24 | Percent Institutions 12.55 |
Upturn AI SWOT
Sanara Medtech Inc
Company Overview
History and Background
Sanara Medtech Inc. focuses on developing, manufacturing, and distributing wound and skin care products. Founded in 2008 (originally as Wound Management Technologies, Inc.), the company has evolved through organic growth and acquisitions to address various wound care needs.
Core Business Areas
- Wound and Skin Care Products: Focuses on advanced wound care solutions, including collagen-based products, hydrogels, and antimicrobial dressings. These products cater to chronic wounds, surgical wounds, burns, and other skin conditions.
- Surgical Reconstruction and Repair: Offers surgical reconstruction and repair products for various procedures, expanding the company's presence in the surgical market.
Leadership and Structure
Ron Nixon is the CEO. The company operates with a functional structure, with departments covering R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- BIAKOu0304Su2122 Antimicrobial Skin and Wound Cleanser: An antimicrobial cleanser used for wound irrigation and debridement. Market share data is not readily available, but competes with products from companies like 3M (MMM) and Smith & Nephew (SNN).
- CellerateRXu00ae Surgical Activated Collagenu00ae: A collagen-based wound matrix used in surgical and chronic wound care. Competes with collagen products from Integra LifeSciences (IART) and ACell.
Market Dynamics
Industry Overview
The advanced wound care market is growing due to an aging population, rising incidence of diabetes and obesity, and increasing prevalence of chronic wounds. The market is highly competitive, with numerous companies offering various wound care solutions.
Positioning
Sanara Medtech is a mid-sized player in the advanced wound care market, focusing on collagen-based and antimicrobial solutions. Its competitive advantage lies in its proprietary collagen technology and focus on niche market segments.
Total Addressable Market (TAM)
The global wound care market is projected to reach over $25 billion. Sanara is positioned to capture a portion of the advanced wound care segment, estimated at ~$10 billion.
Upturn SWOT Analysis
Strengths
- Proprietary collagen technology
- Focus on specific wound care segments
- Experienced management team
- Growing product portfolio
Weaknesses
- Limited brand recognition compared to larger competitors
- Reliance on a relatively small number of key products
- Geographic concentration in the US market
- Smaller sales and marketing team compared to competitors
Opportunities
- Expanding product offerings into adjacent markets
- Geographic expansion into international markets
- Strategic partnerships and acquisitions
- Increasing adoption of advanced wound care technologies
Threats
- Intense competition from larger wound care companies
- Pricing pressures and reimbursement challenges
- Regulatory changes and compliance requirements
- Risk of product liability claims
Competitors and Market Share
Key Competitors
- 3M (MMM)
- Smith & Nephew (SNN)
- Integra LifeSciences (IART)
- Mu00f6lnlycke Health Care (Private)
Competitive Landscape
Sanara Medtech competes with larger, more established companies. Its focus on niche markets and proprietary technology provide some advantages, but it faces challenges in terms of brand recognition and market reach.
Major Acquisitions
Medical Product Innovations (MPI)
- Year: 2019
- Acquisition Price (USD millions): 17.5
- Strategic Rationale: Expanded Sanara's product offerings in surgical reconstruction and repair.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends will need financial data to be pulled and processed.
Future Projections: Analyst projections will need to be collected from financial news or analyst sites.
Recent Initiatives: Recent strategic initiatives are difficult to list without reviewing recent news releases.
Summary
Sanara Medtech is a growing company with a solid base in advanced wound care, particularly collagen-based products. Its smaller size compared to key competitors requires it to focus on strategic acquisitions and niche markets to drive growth. A strong pipeline and successful commercialization are key to increasing market share. Financial performance must be monitored for sustainability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sanara Medtech Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2011-02-22 | CEO - | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 141 | Website https://sanaramedtech.com |
Full time employees 141 | Website https://sanaramedtech.com | ||
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.